The successful development and commercialization of personalized medicines often necessitate use of companion diagnostics (CDx).
Now more than ever, drug developers need an experienced global partner to advance CDx development, who understands how to navigate the technical, regulatory and commercialization nuances to enhance the chances of program success.
Additionally, there is a sharpening focus toward smaller populations treated with drugs for orphan indications and rare diseases, umbrella clinical trials where targeted drugs are used for multiple tumor mutations, and basket clinical trials where targeted drugs focus on multiple tumor indications.
For the full article, please click here.
Related Insights
Managing Informed Consent Samples from Clinical Trials
A set of best practices for the definition, tracking and management of allowable use attributes associated with samples collected in protocol based clinical trials
Biorepository and Specimen Management
Your biological specimens are irreplaceable assets – trust them with a proven partner
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
IQVIA Laboratories Central Laboratory Services
Central laboratory solutions supporting clinical trials around the world
Helping you master your lab data
Improved oversight with your lab data now in full view
NASH and Liver Disease Capabilities
Nonalcoholic Fatty Liver Diseases & Non-alcoholic Steatohepatitis (NAFLD & NASH)
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Pediatric Initiative
Optimizing small blood volumes to prevent canceled tests in clinical trials for pediatric patients
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
